QNCX Quince Therapeutics (NASDAQ) $0.099 intraday 18 Mar 2026: earnings Mar 23 could reset outlook

Quince Therapeutics (QNCX stock) trades at $0.099 intraday on the NASDAQ as investors position ahead of the company’s earnings announcement on Mar 23, 2026. Volume is active at 10,519,528 shares and the share price is down 4.81% today, reflecting heavy selling versus the 50-day average of $1.20. With no product revenue recorded and key clinical milestones expected, this earnings window could change valuations quickly. We track cash, debt, analyst signals and technicals to frame risk and opportunity for traders and longer-term holders.

QNCX stock intraday snapshot and price action

Quince Therapeutics (QNCX stock) is trading at $0.099, down 4.81% from yesterday and inside a daily range of $0.0962–$0.1016. The market cap is about $5.51M and intraday volume of 10,519,528 shares equals a relative volume of roughly 0.16 versus the 20-day average. The 50-day moving average is $1.20 and the 200-day moving average is $1.78, indicating the stock is well below longer-term averages.

QNCX stock earnings calendar and key catalysts

Earnings and company updates are scheduled for Mar 23, 2026, a key date for QNCX stock traders ahead of potential clinical or guidance commentary. The company historically reports no product revenue and investors will focus on cash runway, clinical progress for NOV004, and any timeline for partnering or licensing announcements. Short-term trading may react to trial datapoints, management commentary, or changes to the cash burn outlook.

QNCX stock fundamentals and balance sheet metrics

Quince Therapeutics (QNCX stock) shows EPS -1.20 and a current ratio of 1.12, with $26.29M cash and $17.99M total debt for net cash of $8.30M. Shares outstanding are 55,681,490 and TTM operating cash flow is negative $38.50M, driving a free cash flow deficit. These figures point to ongoing dilution risk unless the company secures financing or partnerships.

Meyka AI grade, analyst mix and valuation signals for QNCX stock

Meyka AI rates QNCX with a score of 67.39 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Public data shows 3 buys and 1 hold from reporting analysts while quantitative company ratings flag weaknesses; that divergence underscores mixed market sentiment.

Technical indicators and short interest impacting QNCX stock

Technicals show QNCX stock is oversold with an RSI of 26.52 and MACD slightly negative while ADX at 32.11 signals a strong trend. The 50-day and 200-day averages sit at $1.20 and $1.78, highlighting the scale of the downmove. Short interest is meaningful at about 14.90% of shares out, which can amplify moves into earnings MarketBeat short interest report.

QNCX stock price targets and Meyka AI forecast

Meyka AI’s forecast model projects a short-term quarterly target of $1.38, compared with the current price of $0.099, implying substantial upside if clinical or partnership news arrives. We present a conservative risk case target of $0.05, a base case of $0.30, and a bull case aligned with the model at $1.38. Forecasts are model-based projections and are not guarantees; sensitivity to trial results and financing events is high. See company stats and valuation at StockAnalysis QNCX statistics.

Final Thoughts

QNCX stock is a high-volatility biotech play trading at $0.099 intraday on NASDAQ as of 18 Mar 2026, ahead of the company’s Mar 23, 2026 earnings and clinical update window. Fundamentals show negative EPS and heavy cash burn, but a net cash position of $8.30M provides a limited runway. Technical indicators are oversold (RSI 26.52) and short interest near 14.90% can amplify moves into earnings. Meyka AI rates QNCX 67.39/100 (Grade B, HOLD) and highlights mixed signals from buy-side analysts and quantitative metrics. Meyka AI’s forecast model projects $1.38 over the next quarter, implying upside of 1,293.94% versus the current $0.099 price; forecasts are model projections and not guarantees. Traders should weigh clinical milestone risk, dilution potential, and the possibility that earnings commentary will drive sharp intraday swings. Meyka AI, an AI-powered market analysis platform, will update coverage after the earnings release and any material disclosures.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.